doi:10.1074/jbc.M203883200 Wang WY, Liu X, Gao XQ, Li X, Fang ZZ
Lets imagine that these biomimetic GLP-1 supplements do pan out as legitimately helpful tools (say, enabling a 5% weight loss with good safety)
The most common adverse events for participants treated with orforglipron (3 mg, 12 mg and 36 mg, respectively) were diarrhea (19%, 21% and 26%) vs
The primary endpoint, change of weight loss over time, was analyzed by repeated-measures ANOVA comparing patients with GLP-1-RAs plus usual care weight management (GLP-1-RA group) to patients with usual care weight management only (UCWM)
The tissue it is supposed to calm simply does not have enough receptors to hear the signal